Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 14 Aug 23 424B5 Prospectus supplement for primary offering
- 7 Jun 21 424B5 Prospectus supplement for primary offering
- 11 Mar 21 424B5 Prospectus supplement for primary offering
- 17 Feb 21 424B4 Prospectus supplement with pricing info
- 16 Feb 21 EFFECT Notice of effectiveness
- 11 Feb 21 S-3/A Shelf registration (amended)
-
4 Feb 21 S-3 Shelf registration
OCUP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of Ocuphire Pharma, Inc. for the registration of its equity and debt securities and to the incorporation by reference therein of our report dated July 1, 2020, with respect to the financial statements of Ocuphire Pharma, Inc., included in Ocuphire Pharma, Inc.’s Current Report on Form 8-K/A dated December 30, 2020, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Detroit, Michigan
February 3, 2021